CTOs on the Move

Houston Foam Plastics Inc

www.houstonfoam.com

 
Houston Foam Plastics Inc is a Houston, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Similar Companies

BZAM Cannabis

Headquartered in Vancouver, BC, BZAM Cannabis is a multi-licensed Canadian cannabis producer focused on branded consumer goods, cultivation, processing and people.

Isus Institute Of Health Care

Isus Institute Of Health Care is a Dayton, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Missouri Highlands Health Care

Missouri Highlands Health Care is non-profit, community-owned organization. Unlike traditional health care practices, Missouri Highlands has a governing body, composed of volunteers from the communities we serve.

Dart NeuroScience

At Dart NeuroScience we are visionaries` innovators` and optimists. We are not a typical pharmaceutical company. We are a discovery catalyst` perfectly positioned and structured to make a serious difference in our world. Curious and creative` hopeful and driven – all joined together to fulfill our vision: protect and enhance the quality of mind. With open minds and open hearts` we stretch our limits every day so that we can continue to improve life and the way we live it.

Furiex

Furiex Pharmaceuticals, Inc., a drug development company, engages in the compound partnering business primarily in the United States. It collaborates with pharmaceutical and biotechnology companies to enhance the value of their drug candidates by applying its novel approach to drug development. The company’s products under development include Eluxadoline1, a mu opioid receptor agonist and delta opioid receptor antagonist, which is in Phase III clinical trials for the treatment of diarrhea-predominant irritable bowel syndrome; and Avarofloxacin1, a Phase III-ready fluoroquinolone antibiotic for the treatment of acute bacterial skin and skin structure infections. It is also developing SYR-472, which is in Phase III clinical trials for the treatment of Type-2 diabetes. In addition, the company has rights to compounds in various stages of development and commercialization, which includes Nesina, Liovel, Oseni, and Kazano for the treatment of Type-2 diabetes, as well as Priligy for the treatment of premature ejaculation. The company was founded in 1998 and is headquartered in Morrisville, North Carolina.